Payment overview · 2025
General Payments
$2,262.97
131 reported records · 27 companies
Healthcare provider profile · identity verified
Jeffrey Ripperda, MD
Allopathic & Osteopathic Physicians|Family Medicine · MURPHYSBORO, IL · NPI 1306869557
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Ripperda, MD received $2,262.97 in general payments during 2025 across 131 reported records.
ABBVIE INC. accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $335.03 | 14.8% | 29 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $187.94 | 8.3% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $184.87 | 8.2% | 14 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $162.60 | 7.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $150.46 | 6.7% | 13 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $148.34 | 6.6% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $116.01 | 5.1% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $93.40 | 4.1% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $87.71 | 3.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.00 | 3.8% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $82.62 | 3.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.56 | 3.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $74.34 | 3.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $73.29 | 3.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.51 | 2.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.74 | 1.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.32 | 1.9% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $35.24 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.92 | 1.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.56 | 1.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $28.72 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.49 | 1.3% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $24.93 | 1.1% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $24.02 | 1.1% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.95 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.32 | 0.7% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.08 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,230.70 | 130 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $187.94 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $175.05 | 16 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $162.60 | 6 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $148.34 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $142.40 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $140.00 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $129.02 | 9 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $93.40 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $87.71 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $85.98 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $84.13 | 9 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $84.13 | 9 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $84.13 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $82.62 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $74.34 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $73.29 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $73.16 | 3 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $67.15 | 3 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $67.15 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.33 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $55.85 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.85 | 5 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $54.09 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.35 | 3 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $44.10 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.74 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.74 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.32 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $35.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.92 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.56 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $28.72 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.49 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $24.02 | 3 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $11.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 269 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
215 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
133 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
269 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 535 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 84 |
| Lisinopril | Lisinopril | 330 | 77 |
| Metformin Hcl | Metformin Hcl | 307 | 58 |
| Omeprazole | Omeprazole | 291 | 53 |
| Carvedilol | Carvedilol | 287 | 59 |
| Eliquis | Apixaban | 269 | 30 |
| Gabapentin | Gabapentin | 267 | 41 |
| Jardiance | Empagliflozin | 215 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 42 |
| Meloxicam | Meloxicam | 177 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 171 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 170 | 39 |
| Famotidine | Famotidine | 166 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 155 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 31 |
| Mirtazapine | Mirtazapine | 143 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 34 |
| Trulicity | Dulaglutide | 133 | 16 |
| Naproxen | Naproxen | 132 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 127 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 35 |
| Buprenorphine Hcl | Buprenorphine Hcl | 115 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 20 |
| Sertraline Hcl | Sertraline Hcl | 105 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 102 | 15 |
| Chlorthalidone | Chlorthalidone | 102 | 24 |
| Allopurinol | Allopurinol | 101 | 23 |
| Furosemide | Furosemide | 101 | 18 |
| Lovastatin | Lovastatin | 100 | 24 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 98 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 92 | 12 |
| Montelukast Sodium | Montelukast Sodium | 92 | 24 |
| Spironolactone | Spironolactone | 90 | 17 |
| Potassium Chloride | Potassium Chloride | 87 | 18 |
| Alendronate Sodium | Alendronate Sodium | 82 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 81 | 13 |
| Finasteride | Finasteride | 78 | 24 |
| Risperidone | Risperidone | 76 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 13 |
| Pregabalin | Pregabalin | 71 | suppressed |
| Torsemide | Torsemide | 71 | 21 |
| Myrbetriq | Mirabegron | 70 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 15 |
| Propranolol Hcl | Propranolol Hcl | 67 | 13 |
| Glipizide | Glipizide | 66 | 12 |
| Simvastatin | Simvastatin | 66 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 65 | suppressed |
| Prednisone | Prednisone | 65 | 37 |
| Doxepin Hcl | Doxepin Hcl | 63 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 12 |
| Trazodone Hcl | Trazodone Hcl | 61 | 12 |
| Baclofen | Baclofen | 57 | suppressed |
| Diazepam | Diazepam | 54 | suppressed |
| Losartan Potassium | Losartan Potassium | 54 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 12 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 43 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Haloperidol | Haloperidol | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 18 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Methadone Hcl | Methadone Hcl | 29 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 29 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 11 |
| Olanzapine | Olanzapine | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 25 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 23 | 23 |
| Clotrimazole | Clotrimazole | 23 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Griseofulvin Ultramicrosize | Griseofulvin Ultramicrosize | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Phenytoin | Phenytoin | 21 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 20 | 11 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Cimetidine | Cimetidine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,262.97 · 131 records | ABBVIE INC. | ABRYSVO, APRETUDE, AREXVY, Auvelity, BEXSERO, BREZTRI, BRIXADI, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, FABRAZYME, FANAPT, GARDASIL 9, GEMTESA, IMCIVREE, LEQVIO, M-M-R II, MOUNJARO, NEXPLANON, NURTEC ODT, Omnipod, Ozempic, PENMENVY, PREVNAR 20, Prolastin-C Liquid, QULIPTA, REXULTI, SHINGRIX, SUBLOCADE, TRELEGY ELLIPTA, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, VYEPTI, WATCHMAN Access System, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error